Overcoming barriers to early disease intervention
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
To the Editor — The editorial in your March 2019 issue1 highlights medicine’s current emphasis on treatment when clinical signs and symptoms of disease are manifested — often at a late stage when curative intervention is impossible and disease reversal is improbable. To date, efforts at early preventive medicine have centered on primary prevention and secondary prevention: the former aims to avoid the onset of disease by both promoting healthy habits and providing preventive clinical services, such as immunization and vaccination, to a broad population; the latter aims to identify individuals at high risk of developing disease and intervene with preventive solutions at an early or asymptomatic stage (Fig. 1). Although immunization and vaccination at the population level have proven powerful approaches for promoting public health, few examples yet exist for secondary prevention in at-risk but ostensibly healthy individuals. Here we describe why secondary prevention has proven so difficult, present some cases for how it could be better implemented, and put forward a rationale for therapeutic drug makers to develop and healthcare systems to adopt (Fig. 2). Although secondary prevention has been a longstanding healthcare imperative, in many cases, trials using this approach have not improved health outcomes2–4. One reason why these have failed is because the interventions often came too late in the disease process. For instance, even though a randomized trial of the small-molecule β-secretase 1 inhibitor verubecestat was targeted to prodromal Alzheimer’s disease patients at high risk for progression, it failed to meet its endpoints, likely because of mistimed (that is, late) intervention. In this trial, the participants already had cognitive symptoms of mild-to-moderate dementia due to the presence of pathological signs of elevated β-amyloid deposits in their brains; thus, the intervention was probably neither sufficiently effective nor early enough in the disease process to have a chance of therapeutic success. Notably, a worse clinical outcome was observed in the verubecestat group than in the placebo group. As a general rule, as diseases advance progressively over time, the combined action of known and unknown causal factors damage the integrity of critical biological networks motifs (redundant feedback and feed-forward loops)5. Gradually, this disrupts the natural flow of essential cell signaling and leads to a loss of biological function, which ultimately manifests itself in overt disease phenotypes and symptoms. Over time, comorbidities and inefficient polypharmacy treatments take over, and organ systems of the human body undergo irreversible, progressive destruction of biological network motifs. Thus, patients lose their physiologic reserve and succumb to underlying conditions, without the ability to restore health. From a physiological standpoint, for individuals at a high risk of developing disease, it makes sense to act at a point sufficiently early in disease processes when biological network motifs still retain sufficient integrity and function to respond to interventions and prevent further decline — or even reverse it. To achieve this goal, three key questions must be answered: first, how to identify those ostensibly healthy individuals at high risk of developing disease before they display clinical signs and symptoms; second, how to assess the therapeutic window of intervention in the trajectory from health to disease where an intervention is most likely to prevent progression to symptoms; and third, how to assess whether a particular individual is at a stage in disease progression that lies within the therapeutic window. Of course, with monogenic diseases, the presence of highly penetrant disease alleles provides a reliable mean of identifying individuals at high risk of developing symptoms. A good example is spinal muscular atrophy (SMA), an autosomal recessive neurodegenerative disease characterized by low levels of the survival motor neuron (SMN) protein due to defective biallelic mutations in the survival motor neuron 1 (SMN1) gene, which causes a loss of motor neurons, progressive muscle weakness, and atrophy of skeletal muscles, ultimately leading to death. There are several types of SMA: the most severe (type 1, Werdnig–Hoffman disease) leads to death by two years of age, with the worst-case scenario involving death in the first month of life (sometimes termed “SMA type 0”). Although the underlying pathology of SMA is not fully understood, deficits in SMN levels and signaling via interacting biological network motifs severely and irreversibly affect neuronal survival6,7. Preclinical animal studies from different groups have revealed the existence of a very short intervention window to increase SMN to optimum levels by replacing the defective SMN1 gene with a functional copy6,8. In those preclinical studies, mouse pups with a deletion in SMN1 (SMNΔ7) treated on postnatal day 1 with a single intravenous injection of 5 × 1011 self-complementary adeno-associated viral vector serotype 9 (scAAV9) particles carrying functional SMN1 achieved complete rescue of motor function, muscle physiology, and lifespan. Treated mice had an average lifespan of more than 400 days, as compared with ~16 days in the untreated animals. Notably, those preclinical studies also showed that the earlier the intravenous injections of the scAAV9-based gene therapy, the greater the therapeutic effect in postnatal mice. As such, this approach has its maximal effect on postnatal day 1, an effect that decreased rapidly with advancing age: injections on day 5 had only a partial effect while injections on postnatal day 10 had no effect. The above studies indicate that interventions designed to increase SMN expression to optimal levels require very early delivery of a functional copy of SMN1 before manifestation of observable signs and symptoms. This observation was confirmed by in vivo pharmacological studies of the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) conducted in SMNΔ7 mice9. Such data provide a strong rationale for timely disease intervention programs in at-risk newborns, including considering surrogate endpoints other than clinical symptoms consistent with SMA type 1. According to the clinical trial study description of Zolgensma, all patients enrolled in the phase 3 trial experienced onset of clinical symptoms consistent with type 1 SMA9; however, Zolgensma worked in only about half of the patients treated. A phase 1 trial showed that efficacy in more patients could be increased at a higher dose, but this increased the likelihood of serious side effects from the treatment, such as severe liver injury, myocardial degeneration and atrial thrombosis. These results suggest a role for prenatal screening for SMN1 mutations, with the possibility of treatment shortly after birth for those who are identified as high risk. Clearly, monogenic diseases are rare in the population, and it should be emphasized that many are still neither simple to comprehend at the genetic level nor easy to predict concerning the timeline for manifestation of clinical symptoms. However, biomedical advances are leading to a better understanding of the intrinsic etiology of some monogenic ailments,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedGenetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice
Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., Carcenac, R., Astord, S., de Moura, A. P., Voit, T., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq514 · Cited by 298
Research works printed but not linked: 8
- Anonymous. Nat. Biotechnol. 37, 197 (2019). · doi:10.1038/s41587-019-0069-3
- Demongeot, J. et al. Int. J. Mol. Sci. 10, 4437–4473 (2009). · DOI
- Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Nat. Rev. Neurol. 14, 214–224 (2018). · DOI · Paper page
- Hickey, R. D. et al. Cell Transplant. 28, 79–88 (2019). · DOI
- Korde, N. et al. JAMA Oncol. 1, 746–754 (2015). · DOI · Paper page
- Landgren, O. et al. Leukemia 33, 2127–2143 (2019). · DOI
- Zhao, A. L. et al. Cancer Manag. Res. 11, 5599–5611 (2019). · DOI
- Pentland, A. Social Physics Vol. 1 (Penguin, 2015).
Cited by
The need for an integrated multi-OMICs approach in microbiome science in the food system
Ferrocino, I., Rantsiou, K., McClure, R., Kostic, T., de Souza, R. S. C., Lange, L., FitzGerald, J., Kriaa, A., Cotter, P., Maguin, E., et al. (2023) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13103 · Cited by 110
Mishima, M. D. V., Da Silva, B. P., Gomes, M. J. C., Toledo, R. C. L., Mantovani, H. C., José, V. P. B. D. S., Costa, N. M. B., Tako, E., & Martino, H. S. D. (2022) · Nutrients · doi:10.3390/nu14224924 · Cited by 23
Metadata
- Authors
- Caicedo, H. H., Hashimoto, D. A., Caicedo, J. C., Pentland, A., & Pisano, G. P.
- Venue
- Nature Biotechnology
- Published
- 2020-05-22
- Volume
- 38
- Issue
- 6
- Pages
- 669-673
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W3027820686
- Cited by
- 182
- References
- 6
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming barriers to early disease intervention. https://app.cochat.ai/papers/10.1038/s41587-020-0550-z
- The paper
- Caicedo, H. H., Hashimoto, D. A., Caicedo, J. C., Pentland, A., & Pisano, G. P. (2020). Overcoming barriers to early disease intervention. Nature Biotechnology. https://doi.org/10.1038/s41587-020-0550-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.